An important area of research to be discussed at the Las Vegas workshop is nutritional strategies for use in combination with Rife frequencies to target malignant cells. Immune enhancing supplements, in combination with frequency applications, helps deliver a one-two punch to malignant cells.

For immune enhancement I use Transfer Factor Plus Advanced Formula exclusively on a daily basis. Occassionally, those with auto-immune diseases do better on regular Transfer Factor. I have seen Transfer Factor alone enable the immune system to kill basal cell carcinomas.

Searching on www.pubmed.org for zeolite and cancer will give you 104 new medical journal papers to add to your reading list. Zeolite has been packaged into a patented nutritional supplement called Natural Cellular Defense. There are others coming onto the market.For cancer or suspected cancer (like a high PSA level), I add Zeolite to the supplement program to give an additional boost to the immune system, assuming muscle testing for the supplement is positive.

Patent applications and even patent submissions are in the public domain and easily accessible from the U.S. Patent Site from the link below. The government grants patent rights to inventors only if they put the patent into the public domain so others can see exactly what the patent is, how it works, and what it applies to. This patent has been assigned by the inventor to Lifelink Pharmaceuticals who owns all rights to it. It is not clear whether rights have been further assigned to others.

United States Patent 6,288,045
Kaufman September 11, 2001
Epithelial cell cancer drug

Abstract

A method of treating epithelial cell cancer comprising administering to a mammalian patient diagnosed as having an epithelial cell cancer a therapeutically effective amount of 4,5 di-cyclo, disilico, dimagnesium, dialumino, oxyo, trihydrate, or its acetate, sulfate, hydrochlorate, or brominate salts. The composition is synthesized from a naturally occurring non-toxic zeolites, and has a 100% kill rate within 72 hours against buccal mucosa and ling squamous epithelial cell cancers. It is not cytoxic to healthy human cells.

Inventors: Kaufman; Harvey (Hudson, OH)
Assignee: Lifelink Pharmaceuticals, Inc. (Stow, OH)
Appl. No.: 591701
Filed: June 9, 2000

BACKGROUND OF THE INVENTION

The present invention is directed to a new and unique anticancer drug, which is identified generically as 4,5 di-cyclo, disilico, dimagnesium, dialumino, oxyo, trihydrate (3Mg++.3Al.sub.2 O.sub.3.3SiO.sub.2.3H.sub.2 O), which is a magnesium aluminosilicate (referred to hereinafter as “MAS”), and which are in the acetate, sulfate, chloride, or brominate form. These compositions come from a class of inorganic aluminosilicate chemicals known as zeolites. The compounds of the present invention are particularly useful in treating epithelial cell cancers in mammals.

The involvement of cancerous epithelial cells, which lead to the formation of solid tumors in humans, in such organs as the lungs, breast, skin, mouth, and colon are known as carcinomas. Most of the epithelial cell cancers are treated using chemotherapeutic agents and these tend to be toxic, and have immunosuppressive side effects. When treated this way, the cancer patient must then wait up to 3 weeks for his next treatment, until his immune system has restored itself.

Cancers involving human epithelial cells come from solid tumors of the breast, lung, stomach, liver, uterus, colon, skin, mouth and uterine cervix can form. Adenocarcinomas from secretory tissue and squamous carcinomas from protective linings are the two basic categories of carcinomas. Epithelial cell based cancers proliferate rapidly respecting no cellular boundaries. To fully understand how to treat epithelial cell based cancer, one must start at the cellular level, this involving use of cell culturing techniques. Present day drugs used for chemotherapy do not directly attack the cancer cell with any great accuracy. Drugs such as Methotrexate and Vincristine are toxic to normal healthy cells and diminish immune system functions. These usually offer the cancer patient extremely disquieting side effects such as diarrhea, hair loss, vomiting and weakness. The toxicity of these drugs often shorten their use or require a very intermittent use. The average chemotherapy cannot be used more than once a month.

A large effort has been put forth by the medical research community to find new drugs for the treatment of epithelial cell based cancers. Carcinoma of the lung, breast, prostate, and colon all together account for more than half of the deaths from cancer in North America. Anticancer drugs have for the most part been categorized into alkylating agents such as cytoxan, antitumor antibiotics such as dactinomycin and antimetablite drugs such as methotrexate. Most, if not all, of these chemotherapies have major side effects and are toxic.

It is well known that chemicals cause 95% of all cancers contracted by humans. Some of the most potent carcinogens are aldehydes, ketones, pyrenes, benzpyrenes, benzene, and nitrosamines. Nitrosamines were looked at early on because they are carcinogenic agents found in cigarette smoke and in the causative agents of rubber polymers.

Zeolites are natural hydrated silicates of aluminum and, usually, either sodium or calcium or both. Zeolites such as sodium aluminosilicate have a unique multi-dimensional structure of cavities into which small to medium size molecules and cells can be trapped. They exist in natural and artificial forms and are used extensively for water softening, as detergent builders, and cracking catalysts. Natural zeolites include analcite, chabuzite, heulandite, natrolite, stilbite, and thomosonite.

Zeolites have been used in animal feed. For example, as reported in “World Food & Drink Report”, Apr. 19, 1990, hydrated sodium calcium aluminosilicate, an anti-caking agent used in animal feed, may reduce levels of aflatoxin in the milk of animals eating contaminated grain. Further, German patent DE19755921 teaches the use of zeolites or klinopitolites, that are used as food additives for human consumption as an aid to health, after they are treated with tribomechanical action to increase their surface area and destabilize their structure to release their chemical potential. These materials are thought to be a useful defense against cancers such as lung cancer, cancer of the colon, and skin cancer, and they are recommended for improving blood circulation.

SUMMARY OF THE INVENTION

The present invention has resulted from the discovery that epithelial cell cancer can be treated by administering to a mammalian patient having an epithelial cell cancer a therapeutically effective amount of 4,5 di-cyclo, disilico, dimagnesium, dialumino, oxyo, trihydrate acetate, sulfate, hydrochlorate, or bromate. The composition of the present invention is synthesized from a naturally occurring non-toxic zeolites, and has a 100% kill rate within 72 hours against buccal mucosa and ling squamous epithelial cell cancers. It is not cytoxic to healthy human cells.

Frequencies on this site are always expressed in the F165 scripting language as F165 programs are precise and can be easily converted for devices that lack automated capabilities. A common conversion is from an F165 program to frequencies for the FSCAN.

#F165 Sample Program
repeat 5
dwell 720
program c
vbackfreq a 0.002478752 0 66.6
vbackfreq b 0.049787068 0 66.6
converge 0 0
12677.6 # protein
converge .17% .1
1662 2774
248666
end repeat

The repeat 5 command causes the program to cycle 5 times.

The dwell is time in seconds so 720 seconds means run for 12 minutes. It you repeated 5 times the total would be 60 minutes.

The FSCAN does not support multiple channels so ignore the scalar waves generated by vbackfreq commands.

The converge function is roughly equivalent to wobble for the FSCAN and converge 0 0 means wobble 0.

The converge .17% .1 command means wobble at .17% of the frequency at an
interval of .1hz. The FSCAN only wobbles with an interval of 1hz so
ignore the .1hz.

Multiply 1662 by .17% = 2.8hz for wobble.

Multiply 2774 by .17% = 4.7hz for wobble.

Multiply 248666 by .17% = 422.7hz for wobble.

At the Las Vegas Workshop 17-19 Feb 2006, new research findings will be discussed. One item on the agenda is using frequencies to mimic the action of a drug as noted in the Jacques Beneviste patent posted previously.

Christopher Bird reviewed Rife’s work and was sent to investigate Gaston Naessens who constructed a microscope with resolution similar to Rife’s. Naessens viewed the lifecycle of somatids, subcellular organisms that he thought were the basis of all life. Chronically ill patients always had abnormal somatid pleomorphic forms in their blood. He developed 714-X, a drug injected into a lymph node in the groin that normalized the somatid life cycle by enhancing the immune system.

With this approach he restored 750 out of 1000 cancer patients to health leading to his persecution and trial in Canada, a trial which he won. Christopher Bird provides a compelling narrative of trial proceedings in The Persecution and Trial of Gaston Naessens.

What if there was a frequency program that could be used to plate zap lymph nodes that generated the same effect. This is an interesting topic of research which will be discussed at the Las Vegas Frequency Research Workshop.

Safety of artificial sweetener called into question by MP

Examples cited in the Commons of the 6,000 products with aspartame

Felicity Lawrence, consumer affairs correspondent
Thursday December 15, 2005
The Guardian

In 1977 Donald Rumsfeld, now George Bush’s defence secretary but then chief executive of the pharmaceutical company GD Searle, publicly stated that he would “call in his markers” to win a licence for aspartame, the sweetener that had been discovered by chance in Searle’s laboratories, according to Roger Williams in the Commons yesterday.

Mr Williams, MP for Brecon and Radnorshire, said in an adjournment debate that there was much controversy about aspartame’s safety at the time but “Rumsfeld appears to have honoured his pledge”. In fact, “the history of the approval of aspartame puts public health regulators and politicians to shame”.

The sweetener is now used in 6,000 products, from crisps such as Walkers prawn cocktail, to soft drinks including Diet Coke and Robinson’s fruit squash, chewing gums such as Orbit, and vitamins pills and medicines. Yet the science on which it was given approval was “biased, inconclusive, and incompetent”. “There is compelling and reliable evidence for this carcinogenic substance to be banned from the UK food and drinks market.”

On the day of his inauguration as president in 1981, with Mr Rumsfeld on his transition team, Ronald Reagan personally wrote an executive order suspending the head of the US Food and Drug Administration’s powers on aspartame, Mr Williams further claimed. One month later Mr Reagan appointed a new head of the regulatory authority, Arthur Hayes, who granted a licence for the sweetener.

“The history of aspartame’s approval is littered with examples showing that if key decision makers found against aspartame’s safety, they were discredited or replaced by industry sympathisers, who were recompensed with lucrative jobs.”

The MP said he was using his parliamentary privilege to highlight “the strong scientific evidence” that the components of aspartame and their metabolites can cause very serious toxic effects on humans, and that long-term aspartame use can cause cancer.

U.S. Patent 6,541,978, April 1, 2003
Method, system and device for producing signals from a substance biological and/or chemical activity
Benveniste; Jacques (Paris, FR); Guillonnet; Didier (Cagnes-sur-mer, FR)

The present invention relates to a method, a system and a device for producing signals from a substance, in particular electric signals, characteristic of the biological and/or chemical activity or the biological and/or chemical behaviour of said substance or an active element contained in said substance. The invention also relates to a method and a system for controlling said signals. The invention also relates to the applications of said method, system and device in particular to the production of active substances and to the detection of defined substances. Finally, the invention relates to signals linked to a biological and/or chemical activity thus produced by said method, system and device.

It is known from the research works of Jacques Benveniste, in particular those described in the patent application WO 94/17406 published on Aug. 4, 1994, that one can pick up, from a biological and/or chemical active element such as a chemical compound, a cell or a micro-organism, or from a substance containing this active element such as a purified preparation, a biological sample, or a living being, an “electromagnetic signal characteristic of the biological and/or chemical activity or of the biological and/or chemical behaviour” of said substance and/or said active element contained in said substance.

It is also known that it is possible to transform, in particular by means of a transducer, such an electromagnetic signal into electric signals. In the following text one also means by “electric signals characteristic of the biological and/or chemical activity or of the biological and/or chemical behaviour of said substance or of an active element contained in said substance” the electric signals derived by signal digitising and/or processing. In this expression the word “characteristic” is used in the meaning where the physical parameters of the electric signals are specific to the substance or to the active element contained in said substance and that the application of these electric signals, via a transducer, to a biological control system makes it possible:

(i) to induce a biological and/or chemical activity on said biological control system relative to that of the substance of origin or the active element it contains;

(ii) to reveal a characteristic of the substance or the active element it contains, at the origin of said electric signals.

The patent application WO 94/17406 published on Aug. 4, 1994, describes a method and a device for picking up “an electromagnetic signal characteristic of a biological and/or chemical activity or of a biological and/or chemical behaviour” from a biological and/or chemical active element such as a chemical compound, a cell or micro-organism, or from a substance containing this active element such as a purified preparation, a biological sample, or a living being.

Since then the inventors have discovered that it is possible to improve the quality of the electromagnetic signal picked up as well as the reliability of the method for producing these signals and that consequently it is possible to produce characteristic electric signals appropriate for industrial applications. The production of such characteristic electric signals implies an exceptional industrial importance.

It thus becomes possible to detect and characterise active elements present in low concentration or in very low concentration in a substance. As examples, it is thus possible to monitor the presence or absence of chemical compounds such as caffeine, ionophoretic-calcium, ovalbumin, propranolol or micro-organisms such as bacterium coli, streptococci, staphilocci whose presence is looked for.

It thus becomes possible to carry out remote tests at several thousands of kilometers since the characteristic signals are electric signals which can immediately be transmitted to the investigation centre of the control laboratory.

It is possible to modify the biological and/or chemical activity or the biological and/or chemical behaviour of a biological receptor system by submitting it to the effects of characteristic electric signals. It also becomes possible to produce new drugs such as solutions depending on signals from arnica, bradykinin, caffeine, nicotine. New production techniques for drugs can be implemented. For example, in the case of certain drugs such as antibiotics, anti-viruses, anti-parasites, anti-mitotics which, to act within bacteria, viruses or cells (tumour cells in particular), must breach the defensive barriers of the above, the signals of these drugs are applied directly into the heart of the bacteria, viruses or cells. In fact, the application of characteristic electric signals, via an appropriate transducer, generates magnetic fields which penetrate into the bacteria, viruses or cells and modify their chemical and/or biological behaviour.

It is possible to store the characteristic electric signals in data banks, using computer techniques. Then, the spread of therapeutic resources, from one point to the other on the planet, is instantaneous according to needs.

MYCOPLASMA

The Linking Pathogen in Neurosystemic Diseases

Several strains of mycoplasma have been “engineered” to become more dangerous. They are now being blamed for AIDS, cancer, CFS, MS, CJD and other neurosystemic diseases.

---

---

PATHOGENIC MYCOPLASMA

A Common Disease Agent Weaponised

There are 200 species of Mycoplasma. Most are innocuous and do no harm; only four or five are pathogenic. Mycoplasma fermentans (incognitus strain) probably comes from the nucleus of the Brucella bacterium. This disease agent is not a bacterium and not a virus; it is a mutated form of the Brucella bacterium, combined with a visna virus, from which the mycoplasma is extracted. [Mycoplasma fermentans is always seen in Lyme infections. When targeted with frequencies it produces undiagnosable Brucella infections. Both organisms must be targeted together along with several other pathogens.]

The pathogenic Mycoplasma used to be very innocuous, but biological warfare research conducted between 1942 and the present time has resulted in the creation of more deadly and infectious forms of Mycoplasma. Researchers extracted this mycoplasma from the Brucella bacterium and actually reduced the disease to a crystalline form. They “weaponised” it and tested it on an unsuspecting public in North America.

Dr Maurice Hilleman, chief virologist for the pharmaceutical company Merck Sharp & Dohme, stated that this disease agent is now carried by everybody in North America and possibly most people throughout the world. [Lyme infections are seen in over 80% of the people I test. Other researchers have similar findings.]

Despite reporting flaws, there has clearly been an increased incidence of all the neuro/systemic degenerative diseases since World War II and especially since the 1970s with the arrival of previously unheard-of diseases like chronic fatigue syndrome and AIDS.

According to Dr Shyh-Ching Lo, senior researcher at The Armed Forces Institute of Pathology and one of America’s top mycoplasma researchers, this disease agent causes many illnesses including AIDS, cancer, chronic fatigue syndrome, Crohn’s colitis, Type I diabetes, multiple sclerosis, Parkinson’s disease, Wegener’s disease and collagen-vascular diseases such as rheumatoid arthritis and Alzheimer’s.

Dr Charles Engel, who is with the US National Institutes of Health, Bethesda, Maryland, stated the following at an NIH meeting on February 7, 2000: “I am now of the view that the probable cause of chronic fatigue syndrome and fibromyalgia is the mycoplasma…”

I have all the official documents to prove that mycoplasma is the disease agent in chronic fatigue syndrome/fibromyalgia as well as in AIDS, multiple sclerosis and many other illnesses. Of these, 80% are US or Canadian official government documents, and 20% are articles from peer-reviewed journals such as the Journal of the American Medical Association, New England Journal of Medicine and the Canadian Medical Association Journal. The journal articles and government documents complement each other.

How the Mycoplasma Works

The mycoplasma acts by entering into the individual cells of the body, depending upon your genetic predisposition.

You may develop neurological diseases if the pathogen destroys certain cells in your brain, or you may develop Crohn’s colitis if the pathogen invades and destroys cells in the lower bowel.

Once the mycoplasma gets into the cell, it can lie there doing nothing sometimes for 10, 20 or 30 years, but if a trauma occurs like an accident or a vaccination that doesn’t take, the mycoplasma can become triggered.

Because it is only the DNA particle of the bacterium, it doesn’t have any organelles to process its own nutrients, so it grows by uptaking pre-formed sterols from its host cell and it literally kills the cell; the cell ruptures and what is left gets dumped into the bloodstream.

II – CREATION OF THE MYCOPLASMA

A Laboratory-Made Disease Agent

Many doctors don’t know about this mycoplasma disease agent because it was developed by the US military in biological warfare experimentation and it was not made public. This pathogen was patented by the United States military and Dr Shyh-Ching Lo. I have a copy of the documented patent from the US Patent Office.

All the countries at war were experimenting with biological weapons. In 1942, the governments of the United States, Canada and Britain entered into a secret agreement to create two types of biological weapons (one that would kill, and one that was disabling) for use in the war against Germany and Japan, who were also developing biological weapons. While they researched a number of disease pathogens, they primarily focused on the Brucella bacterium and began to weaponise it.

From its inception, the biowarfare program was characterised by continuing in-depth review and participation by the most eminent scientists, medical consultants, industrial experts and government officials, and it was classified Top Secret.

The US Public Health Service also closely followed the progress of biological warfare research and development from the very start of the program, and the Centers for Disease Control (CDC) and the National Institutes of Health (NIH) in the United States were working with the military in weaponising these diseases. These are diseases that have existed for thousands of years, but they have been weaponised–which means they’ve been made more contagious and more effective. And they are spreading.

The Special Virus Cancer Program, created by the CIA and NIH to develop a deadly pathogen for which humanity had no natural immunity (AIDS), was disguised as a war on cancer but was actually part of MKNAOMI. Many members of the Senate and House of Representatives do not know what has been going on. For example, the US Senate Committee on Government Reform had searched the archives in Washington and other places for the document titled “The Special Virus Cancer Program: Progress Report No. 8”, and couldn’t find it. Somehow they heard I had it, called me and asked me to mail it to them. Imagine: a retired schoolteacher being called by the United States Senate and asked for one of their secret documents! The US Senate, through the Government Reform Committee, is trying to stop this type of government research.

Smith R (2005) Medical Journals Are an Extension of the Marketing Arm of Pharmaceutical Companies. PLoS Med 2(5): e138

Richard Smith is Chief Executive of UnitedHealth Europe, London, United Kingdom. E-mail: [email protected]

Competing Interests: RS was an editor for the BMJ for 25 years. For the last 13 of those years, he was the editor and chief executive of the BMJ Publishing Group, responsible for the profits of not only the BMJ but of the whole group, which published some 25 other journals. He stepped down in July 2004. He is now a member of the board of the Public Library of Science, a position for which he is not paid.

Published: May 17, 2005

DOI: 10.1371/journal.pmed.0020138

Copyright: © 2005 Richard Smith. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Journals have devolved into information laundering operations for the pharmaceutical industry, wrote Richard Horton, editor of the Lancet, in March 2004 [1]. In the same year, Marcia Angell, former editor of the New England Journal of Medicine, lambasted the industry for becoming primarily a marketing machine and co-opting every institution that might stand in its way [2]. Medical journals were conspicuously absent from her list of co-opted institutions, but she and Horton are not the only editors who have become increasingly queasy about the power and influence of the industry. Jerry Kassirer, another former editor of the New England Journal of Medicine, argues that the industry has deflected the moral compasses of many physicians [3], and the editors of PLoS Medicine have declared that they will not become part of the cycle of dependency between journals and the pharmaceutical industry [4]. Something is clearly up.

The Problem: Less to Do with Advertising, More to Do with Sponsored Trials

The most conspicuous example of medical journals’ dependence on the pharmaceutical industry is the substantial income from advertising, but this is, I suggest, the least corrupting form of dependence. The advertisements may often be misleading [5,6] and the profits worth millions, but the advertisements are there for all to see and criticise. Doctors may not be as uninfluenced by the advertisements as they would like to believe, but in every sphere, the public is used to discounting the claims of advertisers.

The much bigger problem lies with the original studies, particularly the clinical trials, published by journals. Far from discounting these, readers see randomised controlled trials as one of the highest forms of evidence. A large trial published in a major journal has the journal’s stamp of approval (unlike the advertising), will be distributed around the world, and may well receive global media coverage, particularly if promoted simultaneously by press releases from both the journal and the expensive public-relations firm hired by the pharmaceutical company that sponsored the trial. For a drug company, a favourable trial is worth thousands of pages of advertising, which is why a company will sometimes spend upwards of a million dollars on reprints of the trial for worldwide distribution. The doctors receiving the reprints may not read them, but they will be impressed by the name of the journal from which they come. The quality of the journal will bless the quality of the drug.
(Illustration: Margaret Shear, Public Library of Science)

Fortunately from the point of view of the companies funding these trials but unfortunately for the credibility of the journals who publish them these trials rarely produce results that are unfavourable to the companies’ products [7,8]. Paula Rochon and others examined in 1994 all the trials funded by manufacturers of nonsteroidal anti-inflammatory drugs for arthritis that they could find [7]. They found 56 trials, and not one of the published trials presented results that were unfavourable to the company that sponsored the trial. Every trial showed the company’s drug to be as good as or better than the comparison treatment.

By 2003 it was possible to do a systematic review of 30 studies comparing the outcomes of studies funded by the pharmaceutical industry with those of studies funded from other sources [8]. Some 16 of the studies looked at clinical trials or meta-analyses, and 13 had outcomes favourable to the sponsoring companies. Overall, studies funded by a company were four times more likely to have results favourable to the company than studies funded from other sources. In the case of the five studies that looked at economic evaluations, the results were favourable to the sponsoring company in every case.

The evidence is strong that companies are getting the results they want, and this is especially worrisome because between two-thirds and three-quarters of the trials published in the major journals Annals of Internal Medicine, JAMA, Lancet, and New England Journal of Medicine are funded by the industry [9]. For the BMJ, it’s only one-third partly, perhaps, because the journal has less influence than the others in North America, which is responsible for half of all the revenue of drug companies, and partly because the journal publishes more cluster-randomised trials (which are usually not drug trials) [9].

The food you eat may change your genes for life
17 November 2005
NewScientist.com news service
Alison Motluk

IT SOUNDS like science fiction: simply swallowing a pill, or eating a specific food supplement, could permanently change your behaviour for the better, or reverse diseases such as schizophrenia, Huntington’s or cancer.

Yet such treatments are looking increasingly plausible. In the latest development, normal rats have been made to behave differently just by injecting them with a specific amino acid. The change to their behaviour was permanent. The amino acid altered the way the rat’s genes were expressed, raising the idea that drugs or dietary supplements might permanently halt the genetic effects that predispose people to mental or physical illness.

It is not yet clear whether such interventions could work in humans. But there is good reason to believe they could, as evidence mounts that a range of simple nutrients might have such effects.

Two years ago, researchers led by Randy Jirtle of Duke University Medical Center in Durham, North Carolina, showed that the activity of a mouse’s genes can be influenced by food supplements eaten by its mother just prior to, or during, very early pregnancy (New Scientist, 9 August 2003, p 14). Then last year, Moshe Szyf, Michael Meaney and colleagues at McGill University in Montreal, Canada, showed that mothers could influence the way a rat’s genes are expressed after it has been born. If a rat is not licked, groomed and nursed enough by its mother, chemical tags known as methyl groups are added to the DNA of a particular gene.

The affected gene codes for the glucocorticoid receptor gene, expressed in the hippocampus of the brain. The gene helps mediate the animal’s response to stress, and in poorly raised rats, the methylation damped down the gene’s activity. Such pups produced higher levels of stress hormones and were less confident exploring new environments. The effect lasted for life (Nature Neuroscience, vol 7, p 847).

Now the team has shown that a food supplement can have the same effect on well-reared rats at 90 days old – well into adulthood. The researchers injected L-methionine, a common amino acid and food supplement, into the brains of well-reared rats. The amino acid methylated the glucocorticoid gene, and the animals’ behaviour changed. “They were almost exactly like the poorly raised group,” says Szyf, who announced his findings at a small meeting on environmental epigenomics earlier this month in Durham, North Carolina.
“This opens up new ways of thinking about treating and preventing diseases caused by how our DNA is expressed”

Though the experiment impaired well-adjusted animals, the opposite should be possible, and Szyf has already shown that a chemical called TSA that is designed to strip away methyl groups can turn a badly raised rat into a more normal one.

Life Sci. 2004 Jul 9;75(8):955-67

Inhibition of the development of metastases by dietary vitamin C:K3 combination.

Taper HS, Jamison JM, Gilloteaux J, Summers JL, Calderon PB.

Unite de Pharmacocinetique, Metabolisme, Nutrition, et Toxicologie, Universite Catholique de Louvain, Avenue E. Mounier, 73, B-1200 Bruxelles, Belgium. [email protected]

The tumor growth-inhibiting and chemo-potentiating effects of vitamin C and K(3)combinations have been demonstrated both in vitro and in vivo. The purpose of this study was to investigate the influence of orally administered vitamin C and K(3) on the metastasis of mouse liver tumor (T.L.T.) cells implanted in C3H mice. Adult male C3H mice were given water containing vitamin C and K3 (15 g/0.15 g dissolved in 1000 ml) beginning 2 weeks before tumor transplantation until the end of the experiment. T.L.T. cells (106) were implanted intramuscularly in the right thigh of mice. All mice were sacrificed 42 days after tumor transplantation. Primary tumor, lungs, lymph nodes and other organs or tissues suspected of harboring metastases were macroscopically examined. Samples of primary tumors, their local lymph nodes, lungs and main organs such as liver, kidneys, spleen were taken for histological examination. Forty-two percent of control mice exhibited lung metastases and 27% possessed metastases in local lymph nodes whereas 24% of vitamin-treated mice exhibited lung metastases and 10% possessed local lymph nodes metastases. The total number of lung metastases was 19 in control group and 10 in vitamin C and K(3)-treated mice. Histopathological examination of the metastatic tumors from the vitamin-treated mice revealed the presence of many tumor cells undergoing autoschizic cell death. These results demonstrate that oral vitamin C and K(3) significantly inhibited the metastases of T.L.T. tumors in C3H mice. At least a portion of this inhibition was due to tumor cell death by autoschizis.

Autoschizis: a new word in cancer treatment
Denver Naturopathic Clinic

Subject: A combination of vitamin C and vitamin K-3 in a 100:1 ratio causes a unique form of cancer cell destruction that has been named autoschizis.

Just when I thought I could pronounce apoptosis without stumbling, there’s a new word to learn in cancer treatment. The word is autoschizis. Honest.

Researchers started playing around with a combination of vitamin C and a synthetic form of Vitamin K, called K-3 or menadione in the late 1990’s watching what it did to cancer cells. Cancer cells really don’t like this combination. Initial reports described the resulting cell death as due to apoptosis [1] but soon it became apparent that the process of destruction was different and of course needed its own name. The word autoschizis was coined I think by a group headed by J. Gilloteaux.[2] I of course wish he had somehow incorporated his own name in naming the process. When you read the descripitons of what happens to the cancer cells, it sounds like they ran into a guillotine. In one abstract Guilloteaux describes the process of cell death:

“VitC:VitK3-treated cells showed exaggerated membrane damage and an enucleation process in which the perikarya separate from the main cytoplasmic cell body by self-excision. Self-excisions continued for perikarya which contained an intact nucleus surrounded by damaged organelles. After further excisions of cytoplasm, the nuclei exhibited nucleolar segregation and chromatin decondensation followed by nuclear karryorhexis and karyolysis. This process of cell death induced by oxidative stress was named autoschizis because it showed both apoptotic and necrotic morphologic characteristics.”

Or in another description:

“VitC:VitK3-treated cells showed exaggerated membrane damage and an enucleation process in which the perikarya separate from the main cytoplasmic cell body by self-excision. Self-excisions continued for perikarya which contained an intact nucleus surrounded by damaged organelles. After further excisions of cytoplasm, the nuclei exhibited nucleolar segregation and chromatin decondensation followed by nuclear karryorhexis and karyolysis. This process of cell death induced by oxidative stress was named autoschizis because it showed both apoptotic and necrotic morphologic characteristics.”

Let me try and translate this into simple language you can visualize. Apparently the cell membrane forms cuts or schisms which allow the cytoplasm to leak out. The cell shrinks in size until about only 1/3 its original size and only the nucleus and organelles remain surrounded by a tiny ribbon of cytoplasm. If apoptosis is a quiet cell suicide in which the cell curls up and dies, autoschizis is a bit more violent; the cell slashes itself open violently spilling out its insides.

The next Frequency Research Foundation Workshop in Las Vegas will be held at the Atrium Suites Hotel, a Non-Gaming hotel starting Friday evening on 17 February, 9-5 Saturday, and 9-12 on Sunday.

We will be discussing the latest research using the ABPA, F-165, F-Scan, EM machine and the Aurameter and show participants how to use the devices to obtain the best possible results based on recent animal research.

Recommended Preparation

Participants should bring a professional model Cameron Aurameter (available with a Frequency Research Foundation discount from www. dowsing.com) or equivalent device. The chrome model is best for frequency work.

Two books are recommended reading:
Hawkins, David. Power vs. Force. Hay House, 2002.
Oschman, James. Energy Medicine: The Scientific Basis of Energy Therapies . Churchill Livingstone, 2000.

Workshop Agenda

• Background – Evolutionary Biology/Pathogen Lifecycles
• Finding Frequency Sets – hands on exercises
• Equipement Setup – hands on exercises
• Applying Frequencies
• Latest Results in Animal Research
• Case Studies – hands on exercises
• Lastest research on Lyme disease, Avian flu, and other pathogens
• Impact of frequencies on organ systems and cellular function
• Other topics too numerous to mention

On Saturday, Dr. Richard Loyd will discuss his lastest work with the FSCAN and Dr. David Kenney will review his recent animal research.using frequency devices as complementary therapy in his veterinary clinic.

Please e-mail Jeff Sutherland or Dale Fawcett with any requests or suggestions you may have for workshop content.

Participants are required to sign a standard waiver form indicating that these are research results and for use by others at their own risk. Certain material is proprietary and the Patent Office requires participants to sign a standard business non-disclosure to allow future patent proceedings. All information is available for use by participants personally or in a clinic or research center.

Free Pre-Workshop Immunity Seminar
Thursday evening at 7pm on 16 February, all are invited to a free Immunity Workshop covering the latest research on Transfer Factor and its effects on the immune system.

Free Post-Workshop ABPA Certification
Sunday afternoon, 19 February, Dr. Alan Back will run a post workshop ABPA Certification Workshop that will be free to participants. Dr. Back is the inventor of the ABPA and will provide insight into how if functions and using it for best results.

Discounted Hotel Rates
Discounted hotel rates are available by calling the Atrium Suites Hotel and asking for group reservations at 800 330-7728 (www.AtriumSuitesHotel.com) and mentioning the Frequency Research Foundation Workshop. We think you will enjoy this hotel and encourage you to register in our reserved a block of rooms as soon as possible to get reduced rates.

Private Sessions
A few private sessions with Dr. Sutherland are available on Friday and Sunday afternoon. If you are interested contact Dale Fawcett ASAP as these will run out quickly. You can reach Dale at 360 598-6585 or e-mail him at [email protected]. Dale is offering special discounts on pre-workshop Equipment/Education packages to get a head start on training using many of the methodologies that will be discussed during the Workshop.

Registration
To register, click on the Paypal button at the upper left on this page.. If you’ve attended any of the previous Frequency Foundation Workshops you may take a $50 discount by scrolling down to the bottom left side of this page to the lower Paypal link and enter the appropriate amount.